Literature DB >> 7907197

Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones.

D C Jackson1, H E Drummer, L Urge, L Otvos, L E Brown.   

Abstract

Synthetic glycopeptides were used to study possible mechanisms for the reduction observed in the response of influenza virus-specific CD4+ T-cells to strains of virus in which amino acid substitution in the hemagglutinin has led to attachment of a carbohydrate side chain. The peptide NCTLIDALLGDPH stimulates vigorous proliferation of hemagglutinin-specific T-cell clones F1-36 and F1-40 but addition of a heptasaccharide, which approaches the size of natural carbohydrate antennae, eliminated the stimulatory capacity of the peptide. This occurs even though the site of carbohydrate attachment at the N-terminal asparagine lies outside the T-cell determinants encompassed by this sequence. A glycopeptide with only two sugar units was stimulatory for F1-36 but not F1-40, suggesting that peptides with a carbohydrate side chain are able to bind to MHC molecules but that approach of the T-cell receptor of certain clones to the glycopeptide-MHC complex is hindered. Loss of T-cell recognition following attachment of a long carbohydrate side-chain to T-cell determinants is not a general finding because attachment of six carbohydrate units to the peptide, NKYVKQNTLKLA, had little or no effect on the stimulation of a T-cell clone specific for this sequence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907197     DOI: 10.1006/viro.1994.1140

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation.

Authors:  D E Wentworth; K V Holmes
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Immunity to influenza A H9N2 viruses induced by infection and vaccination.

Authors:  X Lu; M Renshaw; T M Tumpey; G D Kelly; J Hu-Primmer; J M Katz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Why Glycosylation Matters in Building a Better Flu Vaccine.

Authors:  Deborah Chang; Joseph Zaia
Journal:  Mol Cell Proteomics       Date:  2019-10-11       Impact factor: 5.911

4.  Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.

Authors:  Keith Wanzeck; Kelli L Boyd; Jonathan A McCullers
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

5.  Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol.

Authors:  I Bacik; H L Snyder; L C Antón; G Russ; W Chen; J R Bennink; L Urge; L Otvos; B Dudkowska; L Eisenlohr; J W Yewdell
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

6.  Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development.

Authors:  Sowmya Sampath; Chris Carrico; Joel Janes; Sairam Gurumoorthy; Claire Gibson; Martin Melcher; Chetan E Chitnis; Ruobing Wang; William R Schief; Joseph D Smith
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

Review 7.  Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection.

Authors:  Michelle D Tate; Emma R Job; Yi-Mo Deng; Vithiagaran Gunalan; Sebastian Maurer-Stroh; Patrick C Reading
Journal:  Viruses       Date:  2014-03-14       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.